RxDoctor Payments Data

Rodrigo Rocha, MD

Nephrology · Lynwood, CANPI 1801847157

Payments from drug & device makers

$54,740in general payments, 2019–2025

Across 173 payments — averaging $316.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$33K
  • Akebia Therapeutics Inc$18K
  • Amgen$672
  • Ardelyx, Inc.$577
  • Mallinckrodt Hospital Products Inc.$281
  • Bayer$275
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$3,55697%
  • Education$1233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,740 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$101,906
Medicare patients
139
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol308$211,051
KerendiaFinerenone122$76,543
DapagliflozinDapagliflozin Propanediol81$41,925
JardianceEmpagliflozin48$26,476
LokelmaSodium Zirconium Cyclosilicate36$23,535
RayaldeeCalcifediol15$17,014
Mycophenolic AcidMycophenolate Sodium12$6,598
Sevelamer Carbonate41$3,966
Calcium Acetate35$2,300
ProsolParenteral Amino Acid 20% No.119$1,466
Nifedipine ErNifedipine14$1,127
Labetalol Hcl17$518
Benazepril Hcl63$443
Losartan Potassium32$352
Tamsulosin Hcl16$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$81$234,586344 claims
BayerKerendia$275$76,543122 claims
Boehringer IngelheimJardiance$38$26,47648 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.

Other nephrology in Lynwood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →